NCT06624488 The Relationship Between Brain Injury Biomarkers in Cerebrospinal Fluid and Blood of Patients After Cardiac Arrest and Prognosis
| NCT ID | NCT06624488 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tang Ziren |
| Condition | Cardiac Arrest (CA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2025-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2023-01-01 with a primary completion date of 2025-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a single-center, prospective, observational study. After successful cardiopulmonary resuscitation for patients with cardiac arrest, they will be transferred to the emergency intensive care unit for further standardized targeted temperature management. When evaluating that the patient meets the indications for lumbar puncture and there are no contraindications for lumbar puncture, lumbar puncture examinations will be completed immediately after return of spontaneous circulation (ROSC), at 24 hours of hypothermia, at 72 hours of hypothermia, and after rewarming. Routine cerebrospinal fluid examinations such as cerebrospinal fluid routine, cerebrospinal fluid biochemistry, and cerebrospinal fluid lactate will be sent for inspection. At the same time, 6 ml of cerebrospinal fluid will be retained and stored in a refrigerator at -80°C. After sample collection is completed, enzyme-linked immunosorbent assay (ELISA) will be used to detect markers such as NSE, HCH-L1, NFL, tau, MBP, GFAP, and S100β. While performing the lumbar puncture examination, peripheral blood will be collected. After centrifugation for 10 minutes (4000 revolutions), serum will be retained and stored in a refrigerator at -80°C to complete the examination of the above markers. After 3 months, the patient\'s neurological function prognosis will be followed up according to the Pittsburgh Cerebral Performance Category (CPC) scale.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old. * Still lack of directive movements after restoration of spontaneous circulation through cardiopulmonary resuscitation. * Advanced life support and targeted temperature management are carried out within 6 hours after return of spontaneous circulation (ROSC). Exclusion Criteria: * Patients with contraindications for lumbar puncture (severe cerebral edema indicated by brain imaging, disappearance of basal cisterns or occult intracranial mass lesions, receiving antiplatelet and anticoagulant therapy, and those with coagulation disorders). * Pregnant patients. * Patients with concomitant traumatic brain injury, stroke, cerebral hemorrhage and other diseases. * Patients whose families do not agree to be enrolled.
Frequently Asked Questions
Who can join the NCT06624488 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cardiac Arrest (CA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06624488 currently recruiting?
Yes, NCT06624488 is actively recruiting participants. Visit ClinicalTrials.gov or contact Tang Ziren to inquire about joining.
Where is the NCT06624488 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06624488 clinical trial?
NCT06624488 is sponsored by Tang Ziren. The trial plans to enroll 30 participants.